Our findings highlight the potential therapeutic relevance of targeting pathways involved in growth factor signaling (e.g., IGF1R and TGFB1), androgen receptor modulation and melanocortin signaling for managing gynecomastia. This evidence concerns the gene TGFB1 and Gynecomastia.